Impact of histological subtypes in patients receiving first-line treatment with enfortumab vedotin/pembrolizumab in advanced metastatic urothelial cancer.

Authors: Aya Abdelnaser, Mitra Shavakhi, Arvind Ravi, Ilana Bensussen Epstein, Bicky Thapa, Paloma Galera, Mary-Ellen Taplin, Joaquim Bellmunt

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4575

Source: Full article

---

Abstract

4575